8-K - Elite Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Elite Pharmaceuticals announced the commercial launch of its generic methadone hydrochloride 5 mg and 10 mg tablets on April 2, 2026, targeting a market with approximately $22 million in 2025 annual retail sales.

Key Takeaways

1Launched generic methadone hydrochloride 5 mg and 10 mg tablets under Elite Laboratories, Inc. label.

2Product indicated for severe pain management and opioid addiction detoxification/maintenance treatment.

32025 annual retail sales for brand and generic methadone tablets were approximately $22 million per IQVIA data.

4Press release furnished as Exhibit 99.1, not deemed filed under Section 18 of the Exchange Act.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a

Regulation Fd

9.01

Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release dated April 2, 2026 | | 104 | | Cover

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1